Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Invuity Announces Fourth Quarter and Full Year 2017 Financial Results

Posted on: 13 Feb 18


Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announces financial results for the three months and year ended December 31, 2017.

Q4 and full year 2017 Highlights

  • Fourth quarter 2017 revenue grew 20% to $11.2 million compared to revenue of $9.4 million in the fourth quarter of 2016.
  • Full year 2017 revenue grew 22% to $39.6 million compared to revenue of $32.5 million in 2016.
  • Disposable revenue in the fourth quarter of 2017 grew 30% to $9.5 million compared to $7.3 million in the fourth quarter of 2016.
  • Disposable revenue in the full year 2017 grew 32% to $32.3 million compared to revenue of $24.5 million in 2016.  
  • PhotonBlade® revenue, which is a component of disposable revenue, was $1.3 million in the fourth quarter.

“We saw a strong debut of PhotonBlade in its first full quarter of launch, which combined with the growth of our other disposable products, resulted in 30% growth in disposable revenue. In addition, I am pleased to report that we made our first commercial sales of the Adapt Waveguide™ in the quarter. The Adapt is a flexible waveguide that can be used in conjunction with a variety of specialized retractors, increasing the number of procedures available to us and broadening our appeal in key surgical specialties, particularly gynecology,” said President and Chief Executive Officer Philip Sawyer. “We believe we are well positioned for strong growth in 2018.”

Financial Results

Revenue was $11.2 million in the fourth quarter of 2017, up 20% from revenue of $9.4 million in the fourth quarter of 2016 driven by strong market acceptance of PhotonBlade and continued growth of the company’s other disposable products. For the 2017 full year, revenue was $39.6 million, an increase of 22% over revenue of $32.5 million in 2016.

Disposable revenue was $9.5 million in the fourth quarter of 2017, up 30% from revenue of $7.3 million in the fourth quarter of 2016. For the 2017 full year, revenue was $32.3 million, a 32% increase over revenue of $24.5 million in 2016. Disposable revenue comes from the sale of our single use devices; waveguides that are attached to our retractors, illuminated aspirators – both Yankauer and Frazier designs – and most recently the addition of PhotonBlade. These revenues are driven by per procedure adoption and represent the primary driver of our growth.

Gross margin for the fourth quarter was 66.7%. This is in line with the expectations we set on our last conference call when we discussed the impact that meaningful PhotonBlade sales and ongoing limited sales of PhotonVue® would have on gross margin. Gross margin was 74.3% for the same period in 2016. For the 2017 full year, gross margin was 70.5% in 2017, compared to 72.8% in 2016.

Total operating expenses for the fourth quarter and full year 2017 were $14.1 million and $63.1 million, respectively compared to $16.0 million and $62.3 million in the prior year periods.

The net loss for the fourth quarter of 2017 was $7.4 million, or $0.43 loss per share, compared to a net loss of $9.6 million, or $0.56 loss per share, for the fourth quarter of 2016. The net loss for full-year 2017 was $39.9 million, or $2.34 loss per share, compared to $40.6 million, or $2.73 loss per share, for 2016.

The Company's balance sheet as of December 31, 2017, included total cash, cash equivalents and short-term investments of $21.0 million.

Business Outlook

For fiscal 2018 Invuity expects revenue to exceed $46 million. The Company expects disposable revenue to grow in excess of 25% in 2018.

Conference Call

Invuity's management will discuss the Company's financial results for the fourth quarter ended and full year ended December 31, 2017, and provide a general business update during a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time today, February 13, 2018. To join the live call, participants may dial 1-877- 556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 4988156. To listen to the live call via Invuity's website, go to, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.

About Invuity®

Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's patented Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery.  Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit

Forward-Looking Statements

This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial projections for 2018.  Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; the adequacy of the Company’s existing cash resources and funding requirements; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.


Company Contact:
Jim Mackaness
Chief Financial Officer
Invuity, Inc.

Mark Klausner
Westwicke Partners

Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)

  Three Months Ended December 31,  Year Ended December 31, 
  2017  2016  2017  2016  
Revenue $ 11,228  $ 9,356  $ 39,619  $ 32,461  
Cost of goods sold   3,739    2,409    11,741    8,824  
Gross profit   7,489    6,947    27,878    23,637  
Operating expenses:             
Research and development   1,853    2,496    9,018    9,908  
Selling, general and administrative   12,272    13,524    54,119    52,409  
Total operating expenses   14,125    16,020    63,137    62,317  
Loss from operations   (6,636)   (9,073)   (35,259)   (38,680) 
Interest expense    (811)   (505)   (2,370)   (2,018) 
Interest income   61    42    222    133  
Other income (expense), net   (21)   (14)   (208)   (44) 
Loss on extinguishment of debt   —    —    (2,303)   —  
Net loss and comprehensive loss $ (7,407) $ (9,550) $ (39,918) $ (40,609) 
Net loss per common share, basic and diluted $ (0.43) $ (0.56) $ (2.34) $ (2.73) 
Weighted-average shares used to compute net loss per common share, basic and diluted   17,154,060    16,930,612    17,051,037    14,868,501  

Condensed Balance Sheets
as of December 31, 2017 and December 31, 2016
 (In thousands, except share and per share amounts)
  December 31,  
 2017  2016  
 (In thousands, except per share data) 
Current assets:      
Cash and cash equivalents$ 17,962  $ 28,300  
Short-term investments  3,040    10,737  
Restricted cash - current  181    181  
Accounts receivable, net  7,421    5,782  
Inventory  7,436    5,052  
Prepaid expenses and other current assets  1,274    1,088  
Total current assets  37,314    51,140  
Restricted cash  727    909  
Property and equipment, net  7,169    8,286  
Other long-term assets  285    —  
Total assets$ 45,495  $ 60,335  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable$ 3,598  $ 2,192  
Accrued and other current liabilities  5,179    6,351  
Short-term debt  5,859    1,362  
Total current liabilities  14,636    9,905  
Deferred rent  2,569    2,721  
Deferred Revenue - LT  36    —  
Long-term debt  29,116    13,261  
Total liabilities  46,357    25,887  
Commitments and contingencies      
Stockholders’ equity:      
Preferred stock, $0.001 par value—10,000,000 shares authorized at December 31, 2017 and December 31, 2016, no shares issued and outstanding at December 31, 2017 and December 31, 2016  —    —  
Common stock, $0.001 par value—100,000,000 shares authorized at December 31, 2017 and December 31, 2016 17,179,258 and 16,950,940 shares issued and outstanding at December 31, 2017 and December 31, 2016  17    17  
Additional paid-in capital  185,255    180,647  
Accumulated deficit  (186,134)   (146,216) 
Total stockholders’ equity  (862)   34,448  
Total liabilities and stockholders’ equity$ 45,495  $ 60,335  


Last updated on: 14/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.